ArticleFrontiers in oncology2026

Pre-treatment inflammatory markers can identify the risk of immune-related toxicity in non-small cell lung cancer patients receiving immune checkpoint inhibitor therapy.

XueYuan Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.